Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 24;15:17534666211034329. doi: 10.1177/17534666211034329

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 4. — Adjusted rate of decline in pre-dose trough FEV₁ (a) and FEV₁ AUC_0–4 (b) over 52 weeks.

Size of data point relative to size of patient cohort; n are for ICS-containing therapies and GFF 18/9.6 ug, respectively.

AUC_0–4, area under the curve 0 to 4 hours post-dose; CI, confidence interval; EOS, eosinophil; FEV₁, forced expiratory volume in 1 second; GFF, glycopyrrolate/formoterol fumarate; ICS, inhaled corticosteroid.